Nov 2023 Articles

Articles
Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial
Lee B, Hong SJ, Rha SW, et al.
Journal:
Atherosclerosis

First published: November 10, 2023 DOI: 10.1016/j.atherosclerosis.2023.117373
View
- Share
Articles
Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
Norata GD, Tokgözoğlu L
Journal:
Eur Heart J

First published: November 8, 2023 DOI: 10.1093/eurheartj/ehad682
View
- Share
Articles
Bempedoic Acid for Primary Prevention of Cardiovascular Events-Reply
Nissen SE, Nicholls SJ, Lincoff AM
Journal:
JAMA

First published: November 7, 2023 DOI: 10.1001/jama.2023.17341
View
- Share
Articles
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance
Ridker PM, Lei L, Louie MJ, et al.
Journal:
Circulation

First published: November 6, 2023 DOI: 10.1161/CIRCULATIONAHA.123.066213
View
- Share
Articles
Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
Tokgözoğlu L, Pirillo A, Catapano AL
Journal:
Eur Heart J

First published: November 4, 2023 DOI: 10.1093/eurheartj/ehad485
View
- Share
Articles
Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing
Corral P, Aguilar Salinas CA, Matta MG, et al.
Journal:
Curr Atheroscler Rep

First published: November 3, 2023 DOI: 10.1007/s11883-023-01160-9
View
- Share
Articles
2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)
Journal:
Arch Med Sci

First published: November 2, 2023 DOI: 10.5114/aoms/174743
View
- Share
Articles
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial
Patel S, Bonaca M, Morrow D, et al.
Journal:
JACC Adv

First published: November 1, 2023 DOI: 10.1016/j.jacadv.2023.100675
View
- Share
Articles
Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry
Kayıkcioglu M, Başaran Ö, Doğan V, et al.
Journal:
J Clin Lipidol

First published: November 1, 2023 DOI: 10.1016/j.jacl.2023.09.013
View
- Share

1 2

Nov 2023 Articles

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events-Reply

Nissen SE, Nicholls SJ, Lincoff AM

Articles

Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance

Ridker PM, Lei L, Louie MJ, et al.

Articles

Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgözoğlu L, Pirillo A, Catapano AL

Articles

Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing

Corral P, Aguilar Salinas CA, Matta MG, et al.

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Articles

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial

Patel S, Bonaca M, Morrow D, et al.

Articles

Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry

Kayıkcioglu M, Başaran Ö, Doğan V, et al.

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Share

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Share

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events-Reply

Nissen SE, Nicholls SJ, Lincoff AM

Share

Articles

Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance

Ridker PM, Lei L, Louie MJ, et al.

Share

Articles

Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgözoğlu L, Pirillo A, Catapano AL

Share

Articles

Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing

Corral P, Aguilar Salinas CA, Matta MG, et al.

Share

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Share

Articles

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial

Patel S, Bonaca M, Morrow D, et al.

Share

Articles

Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry

Kayıkcioglu M, Başaran Ö, Doğan V, et al.

Share